Issue Date: May 4, 2015
… And Invests In Cancer Therapies
Celgene will pay AstraZeneca $450 million to participate in development of MEDI4736, an anti-PD-L1 inhibitor for hematologic malignancies. The pact will focus on combining the AstraZeneca antibody with products in Celgene’s pipeline. Separately, Celgene has paid Northern Biologics, a biotech firm backed by Versant Ventures, $30 million for rights to license oncology antibodies in Northern’s pipeline and to acquire Northern. And Celgene has paid Agios Pharmaceuticals $10 million to expand an earlier pact to develop AG-881, a small molecule in development to treat brain cancer.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society